NOVAVAX INC Goodwill, Acquired During Period
NOVAVAX INC (NVAX) reported Goodwill, Acquired During Period of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Notes › Intangible Assets › Goodwill and Other
us-gaap:GoodwillAcquiredDuringPeriod · last filed 2022-03-01
- NOVAVAX INC goodwill, acquired during period for the quarter ending 2020-12-31 was $0.00.
- NOVAVAX INC goodwill, acquired during period for the quarter ending 2020-09-30 was $194.00K.
- NOVAVAX INC goodwill, acquired during period for the quarter ending 2013-12-31 was $126.00K.
- NOVAVAX INC goodwill, acquired during period for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- NOVAVAX INC goodwill, acquired during period for fiscal 2020 was $70.66M.
- NOVAVAX INC goodwill, acquired during period for fiscal 2019 was $0.00.
- NOVAVAX INC goodwill, acquired during period for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
| Period end | Goodwill, Acquired During Period 3 month | Goodwill, Acquired During Period 6 month | Goodwill, Acquired During Period 9 month | Goodwill, Acquired During Period 12 month | Goodwill, Acquired During Period 12 month as first filed |
|---|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-01 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $194.00K derived: sum of 2 quarters · filed 2022-03-01 | $70.66M 10-K · filed 2022-03-01 | ||
| 2020-09-30 | $194.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $70.66M 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $70.47M 10-Q · filed 2020-08-10 | ||||
| 2019-12-31 | $0.00 10-K · filed 2021-03-01 | ||||
| 2014-12-31 | $0.00 10-K · filed 2015-02-27 | ||||
| 2013-12-31 | $126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $25.42M 10-K · filed 2015-02-27 | $26.24M 10-K · filed 2014-03-12 | ||
| 2013-09-30 | $25.30M 10-Q · filed 2014-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |